GSK 3008348

GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer[1][2][3][4].

Product Specifications

CAS Number

[1629249-33-7]

UNSPSC

12352005

Target

Integrin; TGF-β Receptor

Type

Reference compound

Related Pathways

Cytoskeleton; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/GSK_3008348.html

Purity

98.04

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(O)C[C@@H](C1=CC(N2N=C(C)C=C2C)=CC=C1)CN3C[C@H](CCC(N4)=CC=C5C4=NCCC5)CC3

Molecular Formula

C29H37N5O2

Molecular Weight

487.64

References & Citations

[1]Anderson Niall Andrew, et al. Preparation of naphthyridine derivatives useful as αvβ6 integrin antagonists. From PCT Int. Appl. (2014), WO 2014154725 A1 20141002.|[2]Tang J, et al. Heat Shock Protein 60 Is Involved in Viral Replication Complex Formation and Facilitates Foot and Mouth Virus Replication by Stabilizing Viral Nonstructural Proteins 3A and 2C. mBio. 2022 Oct 26;13 (5) :e0143422. |[3]Han Z, et al. Integrin αVβ1 regulates procollagen I production through a non-canonical transforming growth factor β signaling pathway in human hepatic stellate cells. Biochem J. 2021 May 14;478 (9) :1689-1703.